AbbVie (ABBV) – Corporate News
-
AbbVie (ABBV): New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary and All Secondary Endpoints
-
AbbVie (ABBV) Reports Phase 3 SELECT-GCA Study of Upadacitinib Showed Positive Results in Patients With Giant Cell Arteritis
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to ABBV Stock Lookup